Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
March 2018
-
Media ReleaseSandoz receives positive CHMP opinion for proposed biosimilar infliximabSandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a…
-
Media ReleasePhase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MSEXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate…
-
Media ReleaseNovartis drug Tasigna® approved by FDA to treat children with rare form of leukemiaTasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA…
-
Media ReleaseNovartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapiesCollaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development…
-
Media ReleaseAveXis Enters into Licensing Agreement with GenethonIncludes exclusive worldwide rights to AAV9-SMN product and route of administration CHICAGO and ÉVRY, France, March 13, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) and Genethon today…
-
Key ReleaseNovartis announces changes to the Executive Committee to support strategic prioritiesBertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger…
-
Media ReleaseNovartis expands alliance with Science 37 to advance virtual clinical trials programNovartis and Science 37 commit to launch up to 10 trials with increasing decentralization over three years, scaling to "site-less" model Agreement builds on our long-standing investment in and…
-
Media ReleaseNovartis' Xolair® recommended in new global chronic urticaria guidelineXolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…
-
Media ReleaseNovartis shareholders approve all resolutions proposed by Board of Directors at the Annual General MeetingShareholders approve 21st consecutive dividend increase to CHF 2.80 (+2%) per share for 2017; representing a 3.6% yield and approximately 67% payout of free cash flow Dr. Joerg Reinhardt…
-
Media ReleaseNovartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosisNovartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis'…
February 2018
-
Media ReleaseAveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results– On track to request pre-BLA meeting with FDA in Q2 2018 – – Intends to initiate pivotal trial in SMA Type 1 in Europe and multi-national pre-symptomatic SMA study in the first half of…
-
Media ReleaseTreatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflationUltibro® Breezhaler® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo CLAIM is the first study to…
Pagination
- ‹ Previous page
- 1
- …
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- …
- 88
- › Next page